Vir Biotechnology reports Q4 and full year 2024 financial results and pipeline updates

Vir Biotechnology, Inc.

2024-FY EPS reported -$3.83 revenue$74,205,000

Cash, cash equivalents and investments of $1.10 billion as of Dec 31, 2024, providing cash runway into mid-2027.
Net loss for Q4 2024 was $104.6 million ($0.76 per share) vs $116.0 million ($0.86 per share) in Q4 2023.
Phase 3 ECLIPSE registrational program in chronic hepatitis delta on track for first patient in first half of 2025.
Initial Phase 1 data for VIR-5818 showed tumor shrinkage in 50% (10/20) of participants at doses ≥400 µg/kg.
Company plans to initiate Phase 1 study of VIR-5525, dual-masked EGFR-targeting T-cell engager, in first half 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.